期刊文献+

椎体成形术联合唑来膦酸治疗老年COPD患者骨质疏松性胸椎压缩骨折的近期疗效分析 被引量:15

Percutaneous vertebroplasty combined with zoledronic acid in treatment of compression fracture of thoracic vertebra in elderly COPD patients
下载PDF
导出
摘要 目的:探讨椎体成形术(PVP)联合唑来膦酸治疗老年骨质疏松性胸椎单发椎体压缩骨折(OVCF)合并慢性阻塞性肺疾病(COPD)患者的临床疗效。方法:选取老年COPD并发OVCF患者21例行PVP术,术后2 d静脉滴注唑来膦酸。检测术前及术后1年骨密度(BMD),应用日常生活自理能力(ADL)量表评估患者生活质量;术前、术后1周、1年应用视觉模拟评分法(VAS)评价疼痛程度,监测肺活量(VC)、用力肺活量(FVC)、1秒钟用力呼气容积(FEV1)/FVC的比值(FEV1%);分析VAS与VC、FVC、FEV1%之间的相关性。结果:术后1年ADL评分、腰椎及股骨颈BMD均高于术前,差异有统计学意义(P<0.01或P<0.05)。术后1周,VC和FVC显著优于术前(P<0.01),术后1年时该指标进一步改善(P<0.01)。术后1年,FEV1%值较术前显著改善(P<0.01);Spearman相关分析表明VAS评分与VC(r=-0.916,P<0.05)、FVC(r=-0.981,P<0.05)呈显著负相关。结论:PVP联合唑来膦酸注射液治疗老年OVCF合并COPD患者手术能迅速缓解疼痛,恢复肺功能,改善患者的生活质量,增加患者骨密度。 Objective:To explore percutaneous vertebroplasty( PVP) combined with zoledronic acid in treatment of compression fracture of thoracic vertebra(OVCF)in elderly patients complicated with chronic obstructive pulmonary disease(COPD). Methods:A total of 21 COPD patients complicated with OVCF were collected and received PVP surgery. And two days later all patients were given zoledronic acid intravenously. The bone mineral density( BMD) before and after PVP was detected. Quality of life was assessed by activi-ties of daily living( ADL) scale. Visual analogue score( VAS) was applied to evaluate the pain intensity before surgery,and one week and one year after surgery. Along with this the vital capacity(VC),forced vital capacity(FVC),1 second forced expiratory volume(FEV1)/FVC ratio(FEV1%)were monitored. Correlations between VAS with VC,FVC and FEV1% were analyzed respectively. Results:ADL scores as well as BMD of lumbar spine and femoral neck were higher one year after PVP than those before surgery and the difference was statistically significant(P〈0. 01 or P〈0. 05). VC and FVC were obviously better one week later than those before surgery(P〈0. 01),and the indexes were further improved one year after PVP surgery(P〈0. 01). One year later FEV1% improved significantly when compared with preoperative(P〈0. 01). Spearman correlation analysis showed that VAS score was negatively correlated with VC (r= -0. 916,P〈0. 05)and FVC(r= -0. 981,P〈0. 05). Conclusion:PVP combined zoledronic acid injection in treatment of elder-ly COPD patients with OVCF can rapidly relieve the pain and recover the lung function,then improve the quality of life and increase bone mineral density of patients.
作者 冯和林
出处 《川北医学院学报》 CAS 2015年第4期458-461,共4页 Journal of North Sichuan Medical College
基金 中国高校医学期刊临床专项资金(11522770)
关键词 椎体成形术 骨质疏松性压缩骨折 唑来膦酸 慢性阻塞性肺疾病 Percutaneous vertebroplasty Osteoporotic compression fractures Zoledronic acid Chronic obstructive pulmonary disease
  • 相关文献

参考文献15

  • 1Dong R,Chen L,Gu Y,et al.Improvement in respiratory function after vertebroplasty and kyphoplasty[J].Int Orthop,2009,33(6):1689-1694.
  • 2Silva DR,Coelho AC,Dumke A,et al.Osteoporosis prevalence and associated factors in patients with COPD:a cross-sectionalstudy[J].Respir Care,2011,56(7):961-968.
  • 3Graat-Verboom L,Smeenk FW,van den Borne BE,et al.Risk factors for osteoporosis in Caucasian patients with moderate chronic obstructive pulmonary disease:a case control study[J].Bone,2012,50(6):1234-1239.
  • 4袁松,曾凡伟.脊柱骨质疏松性压缩骨折治疗进展[J].川北医学院学报,2014,29(4):406-410. 被引量:11
  • 5颜兴伟,杨玉金,王国平,王小梅,刘菁萍,许秀柏.骨质疏松症危险因素的病例-对照研究[J].中国慢性病预防与控制,2005,13(2):69-72. 被引量:34
  • 6任辉,魏秋实,江晓兵,崔健超,唐晶晶,林顺鑫,梁德,庄洪,姚珍松,张顺聪,杨志东.糖皮质激素性骨质疏松的研究新进展[J].中国骨质疏松杂志,2014,20(9):1138-1142. 被引量:37
  • 7Mathioudakis AG,Amanetopoulou SG,Gialmanidis IP,et al.Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients:aggravating or beneficial?[J].Respirology,2013,18(1):147-153.
  • 8Sheng S,Zhenzhong S,Weimin J,et al.Improvement in Pulmonary Function of Chronic Obstructive Pulmonary Disease(COPD)Patients With Osteoporotic Vertebral Compression Fractures(OVCFs)After Kyphoplasty Under Local Anesthesia[J].Int Surg,2015,100(3):503-509.
  • 9江红卫,崔学文,黄永辉,徐晓峰,狄镇海.经皮椎体成形术治疗骨质疏松性椎体骨折的临床疗效分析[J].现代预防医学,2012,39(23):6369-6370. 被引量:28
  • 10Chandra RV,Yoo AJ,Hirsch JA.Vertebral augmentation:update on safety,efficacy,cost effectiveness and increased survival?[J].Pain Physician,2013,16(4):309-320.

二级参考文献88

  • 1王玲,王宏,张卫国,李建军,刘玉槐.鲑鱼降钙素治疗老年骨质疏松症的疗效观察[J].中国骨肿瘤骨病,2005,4(1):27-28. 被引量:23
  • 2邝建,王敏霓,王声涌,崔长安,刘国宁.中老年知识分子骨质疏松危险因素病例-对照研究[J].中华内分泌代谢杂志,1996,12(1):12-16. 被引量:7
  • 3刘保卫,王岩,刘郑生,肖嵩华,张永刚,毛克亚.闭合复位后椎体成型术治疗骨质疏松性椎体压缩骨折[J].中国脊柱脊髓杂志,2005,15(11):651-653. 被引量:21
  • 4Sambrook P, Cooper C. Osteoporosis [J]. Lancet, 2006,367: 2010-2018.
  • 5Johnell O,Kanis J. Epidemiology of osteoporotic fractures[J]. Osteoporos Int, 2005,16 (Suppl 2) : S3-S7.
  • 6Stevenson M, Jones M L, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal ostcoporosis [J]. Health Technol Assess, 2005,9 : 1 -160.
  • 7Wellington K,Goa K L. Zoledronic acid:a review of its use in the management of bone metastases and hypercalcaemia of malignancy[J]. Drugs, 2003,63 : 417-437.
  • 8McClung M,Miller P,Recknor C, Mesenbrink P, Bucci-rechtweg C, Benhamou C L. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass : a ran domized controlled trial [J]. Obstet Gynecol, 2009, 114: 999- 1007.
  • 9Higgins J P T, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2[EB/OL]. (2009- 09) [2011-03-01]. http:// www. cochrane-handbook, org.
  • 10Hwang J S,Chin L S,Chen J F,Yang T S,Chen P Q,Tsai K S, et al. The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis[J]. J Bone Miner Metab, 2011,29,328-333.

共引文献158

同被引文献132

  • 1原小兵,马玉伟.唑来膦酸对骨质疏松症患者骨代谢和骨转换指标的影响[J].中国合理用药探索,2019,16(3):82-84. 被引量:5
  • 2Spiegel R, Nawroth PP, Kasperk C.The effect of zoledronic acid on the fracture risk in men with osteoporosis.Journal of endocrinological investigation,2014,37 (3):229-232.
  • 3Ruza I,Miffakhraee S,OrwoU E,et al.Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions. Therapeutic advances in musculoskeletal disease,2013, 5(4):182-198.
  • 4Pacheco KD, Freitas LG, Avila MP. Freitas-Neto CA, de Oliveira Fagundes WB, Ribeiro M,et al.Unihteral uveitis with vitreous haze following zoledronic Acid therapy for osteoporosis.Seminars in ophthalmology, 2015,30(3):232-234.
  • 5Costa L,Badia X,Chow E,et al.Impact of skeletal complications on patients'quality of life,mobility,and functional independence.Support Care Cancer,2008,16:879-889.
  • 6Poon M,Zeng L,Zhang L,et al.Incidence of skeletalrelated events over time from solid tumour bone metastases reported in randomised trials using bonemodifying agents.Clin oncol,2013,25(7):435-444.
  • 7Smith HS,Barkin RL.Painful boney metastases.American J therapeutics,2014,21(2):106-130.
  • 8Young-Kwon Ko,Yoon-Hee Kim.Percutaneous vertebroplasty for painful spinal metastasis:a good option for better quality of life.Korean J Anesth,2013,64(3):201-203.
  • 9Seo SS,Lee DH,Kim HJ,et al.Percutaneous vertebroplasty at C7 for the treatment of painful metastases.Korean J Anesth,2013,64:276-279.
  • 10Nas OF,Inecikli MF,Kacar E,et al.Effectiveness of percutaneous vertebroplasty in cases of vertebral metastases.Diagnostic and interventional imaging,2015,96(11):1161-1168.

引证文献15

二级引证文献105

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部